Gumarontinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Gumarontinib
- Molecular weight
- 459.5
- Structure (SMILES)
- Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1
- glumetinib
- Glumetinib
- Glumetinib [WHO-DD]
- Glumetinib tablets
- Glumetinib Tablets
- glumetinib who dd
- gumarontinib
- Gumarontinib
- gumarontinib [INN]
- Gumarontinib [MI]
- gumarontinib inn
- gumarontinib mi
- Gumarontinib Tablets
- sc c244
- Sc-c244
- scc244
- Scc244
- CAS registry numbers
- 1642581-63-2
- ChEMBL ID
- CHEMBL4594400
- InChIKey
- RYBLECYFLJXEJX-UHFFFAOYSA-N
- PubChem compound IDs
- 117797905
- FDA ingredient codes (UNII)
- 7JTT036WGX
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- gumarontinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- MET proto-oncogene, receptor tyrosine kinase
- Gene symbol
- MET
- Protein identifier
- P08581
- Median affinity
- 9.38
- Affinity units
- pIC50
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_1001480
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- NCT03457532
- NCT03466268
- NCT06452433
- Hydrogen bond acceptors
- 11
- Hydrogen bond donors
- 0
- Polar surface area
- 117.79
- Calculated partition coefficient (ALogP)
- 2.12
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 33
- Molecular formula
- C21H17N9O2S
- Monoisotopic mass
- 459.12259199
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (12)
- A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
- A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
- A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
- Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
- Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.
- Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
- Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Single Dose Glumetinib in Healthy Chinese Male Subjects
- Study to Evaluate the Safety and Anti-tumor Activity of SCC244
In development for (2)
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2